Exploration of molecular signatures associated with different clinical features of Takayasu arteritis based on a prospective cohort study

Clin Immunol. 2023 Sep 27:109794. doi: 10.1016/j.clim.2023.109794. Online ahead of print.ABSTRACTTakayasu arteritis (TAK) is complicated disorder without reliable biomarkers. Here, we aimed to explore TAK-associated factor panels and their changes after biologic treatment. Five factor panels were identified: 1. systemic inflammation: C3, ESR, CRP, PLT, IL-6, C4, and IgG; 2. vascular inflammation: YKL40, IL-16, PTX3, and CCL2; 3. immune regulation panel: IL-10, IFN-γ, CCL5, and MMP1; 4. angiogenesis and fibrosis: FGF, PDGFAB, and VEGF; and 5. vascular remodeling: CD19+ B cell ratio, MMP3, and leptin. Panel 1 parameters were closely related to disease activity, while Panel 5 parameters, particularly CD19+ B cell ratio and leptin, were significantly higher in ischemic patients. After treatment, tocilizumab had a stronger inhibitory effect on Panel 1 parameters, PTX3, and YKL-40, while adalimumab led to an increase in IL-16, CCL2, and leptin levels. Altogether, these data expand our knowledge regarding molecular background in TAK development and shed light on precise treatment in future studies.PMID:37774906 | DOI:10.1016/j.clim.2023.109794
Source: Clinical Immunology - Category: Allergy & Immunology Authors: Source Type: research